ClinicalTrials.gg
Not yet recruitingNCT07951645Updated Nov 20, 2026

Effects of Lung Recruitment on Cerebral Hemodynamics(LRCH)

An interventional study of Method A: Incremental PEEP Recruitment Maneuver and Method B: Sustained Inflation Maneuver in Lung Recruitment Maneuver and Mechanical Ventilation, sponsored by First People's Hospital of Chenzhou. Not yet recruiting. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by First People's Hospital of Chenzhou · Not applicable, Interventional, and Other

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Patients receiving invasive mechanical ventilation may develop alveolar derecruitment due to atelectasis, secretion retention, changes in body position, or acute respiratory distress syndrome. Lung recruitment maneuvers reopen partially collapsed alveoli by briefly increasing transpulmonary pressure, thereby improving lung volume and oxygenation; however, elevated airway pressure may also affect venous return, mean arterial pressure, and carbon dioxide elimination, and thus alter cerebral blood flow. Therefore, improved oxygenation does not necessarily indicate stable cerebral circulation.

At present, when selecting a lung recruitment modality in clinical practice, clinicians often rely on oxygenation response, respiratory mechanics, and operator experience, while dynamic observation of cerebral hemodynamics remains relatively insufficient. Recording only two time points before and after the maneuver may miss transient but clinically meaningful changes during pressurization, maintenance of high pressure, and recovery. Therefore, under controlled and safe conditions, it is necessary to use three commonly used clinical lung recruitment maneuvers as observational scenarios to describe cerebral hemodynamic changes during lung recruitment and to explore possible physiological factors in conjunction with cardiac output, systemic blood pressure, carbon dioxide, and respiratory mechanics. The findings are expected to provide a physiological basis for bedside cerebral perfusion monitoring and risk identification; however, short-term changes in Vm alone cannot prove that a particular maneuver is safer or improves long-term outcomes.

02

Conditions studied

  • Lung Recruitment Maneuver
  • Mechanical Ventilation

Keywords

  • Lung recruitment maneuver
  • Cerebral hemodynamics
  • Transcranial Doppler
  • Positive end-expiratory pressure
  • Mean flow velocity
  • Randomized self-controlled study
03

In context

Lead sponsor

First People's Hospital of Chenzhou is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (1)Age 18 years or older.
  • (2)Receiving invasive mechanical ventilation through an endotracheal tube or tracheostomy.
  • (3)A clinical indication for a lung recruitment maneuver, with an expectation that three bedside observation periods can be completed during hospitalization.
  • (4)An adequate temporal acoustic window for reproducible transcranial Doppler recordings and an adequate echocardiographic window for reproducible left ventricular outflow tract velocity-time integral measurements.
  • (5)Axillary temperature between 36.0°C and 37.3°C.
  • (6)Written provided by the participant or a legally authorized representative.

Exclusion criteria

Exclusion Criteria:

  • (1)Current use of vasoactive medications.
  • (2)Known severe cardiac dysfunction or severe pulmonary hypertension.
  • (3)Undrained pneumothorax, marked airflow limitation, giant pulmonary bullae, or another condition associated with a high risk of barotrauma.
  • (4)Known markedly elevated intracranial pressure or escalating treatment for intracranial hypertension.
  • (5)Any other condition that, in the investigator's judgment, makes participation inappropriate.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Sequence 1: A-B-C

    A researcher who is not involved in outcome assessment will generate the randomized sequence. The three lung recruitment maneuvers will be designated A, B, and C and assigned in one of six sequences: ABC, ACB, BAC, BCA, CAB, or CBA. Consecutive observation periods will be separated by at least 12 hours. Before each period, the clinical indication for lung recruitment and the stability of vital signs will be reassessed, and the patient's position and sedation regimen will be confirmed to have remained substantially unchanged. If these conditions are not met, the period will be postponed or canceled. Any study withdrawal or early termination of a maneuver will be documented as specified above; newly enrolled participants must not be used to replace such events without reporting them.

    Procedure: Method A: Incremental PEEP Recruitment Maneuver · Procedure: Method B: Sustained Inflation Maneuver · Procedure: Method C: Pressure-Controlled Ventilation

  • Experimental
    Sequence 2: B-C-A

    A researcher who is not involved in outcome assessment will generate the randomized sequence. The three lung recruitment maneuvers will be designated A, B, and C and assigned in one of six sequences: ABC, ACB, BAC, BCA, CAB, or CBA. Consecutive observation periods will be separated by at least 12 hours. Before each period, the clinical indication for lung recruitment and the stability of vital signs will be reassessed, and the patient's position and sedation regimen will be confirmed to have remained substantially unchanged. If these conditions are not met, the period will be postponed or canceled. Any study withdrawal or early termination of a maneuver will be documented as specified above; newly enrolled participants must not be used to replace such events without reporting them.

    Procedure: Method A: Incremental PEEP Recruitment Maneuver · Procedure: Method B: Sustained Inflation Maneuver · Procedure: Method C: Pressure-Controlled Ventilation

  • Experimental
    Sequence 3: C-A-B

    A researcher who is not involved in outcome assessment will generate the randomized sequence. The three lung recruitment maneuvers will be designated A, B, and C and assigned in one of six sequences: ABC, ACB, BAC, BCA, CAB, or CBA. Consecutive observation periods will be separated by at least 12 hours. Before each period, the clinical indication for lung recruitment and the stability of vital signs will be reassessed, and the patient's position and sedation regimen will be confirmed to have remained substantially unchanged. If these conditions are not met, the period will be postponed or canceled. Any study withdrawal or early termination of a maneuver will be documented as specified above; newly enrolled participants must not be used to replace such events without reporting them.

    Procedure: Method A: Incremental PEEP Recruitment Maneuver · Procedure: Method B: Sustained Inflation Maneuver · Procedure: Method C: Pressure-Controlled Ventilation

  • Experimental
    Sequence 1: A-C-B

    A researcher who is not involved in outcome assessment will generate the randomized sequence. The three lung recruitment maneuvers will be designated A, B, and C and assigned in one of six sequences: ABC, ACB, BAC, BCA, CAB, or CBA. Consecutive observation periods will be separated by at least 12 hours. Before each period, the clinical indication for lung recruitment and the stability of vital signs will be reassessed, and the patient's position and sedation regimen will be confirmed to have remained substantially unchanged. If these conditions are not met, the period will be postponed or canceled. Any study withdrawal or early termination of a maneuver will be documented as specified above; newly enrolled participants must not be used to replace such events without reporting them.

    Procedure: Method A: Incremental PEEP Recruitment Maneuver · Procedure: Method B: Sustained Inflation Maneuver · Procedure: Method C: Pressure-Controlled Ventilation

  • Experimental
    Sequence 1: B-A-C

    A researcher who is not involved in outcome assessment will generate the randomized sequence. The three lung recruitment maneuvers will be designated A, B, and C and assigned in one of six sequences: ABC, ACB, BAC, BCA, CAB, or CBA. Consecutive observation periods will be separated by at least 12 hours. Before each period, the clinical indication for lung recruitment and the stability of vital signs will be reassessed, and the patient's position and sedation regimen will be confirmed to have remained substantially unchanged. If these conditions are not met, the period will be postponed or canceled. Any study withdrawal or early termination of a maneuver will be documented as specified above; newly enrolled participants must not be used to replace such events without reporting them.

    Procedure: Method A: Incremental PEEP Recruitment Maneuver · Procedure: Method B: Sustained Inflation Maneuver · Procedure: Method C: Pressure-Controlled Ventilation

  • Experimental
    Sequence 1: C-B-A

    A researcher who is not involved in outcome assessment will generate the randomized sequence. The three lung recruitment maneuvers will be designated A, B, and C and assigned in one of six sequences: ABC, ACB, BAC, BCA, CAB, or CBA. Consecutive observation periods will be separated by at least 12 hours. Before each period, the clinical indication for lung recruitment and the stability of vital signs will be reassessed, and the patient's position and sedation regimen will be confirmed to have remained substantially unchanged. If these conditions are not met, the period will be postponed or canceled. Any study withdrawal or early termination of a maneuver will be documented as specified above; newly enrolled participants must not be used to replace such events without reporting them.

    Procedure: Method A: Incremental PEEP Recruitment Maneuver · Procedure: Method B: Sustained Inflation Maneuver · Procedure: Method C: Pressure-Controlled Ventilation

Interventions

  • ProcedureMethod A: Incremental PEEP Recruitment Maneuver

    Before method A, original ventilator settings are kept stable for at least 10 minutes. Baseline ventilator parameters, vital signs, end-tidal carbon dioxide (EtCO2), transcranial Doppler (TCD) parameters, and left ventricular outflow tract velocity-time integral (LVOT-VTI) are recorded. Pressure-controlled ventilation is used with inspiratory driving pressure \<=15 cmH2O, respiratory rate 16/min, I:E=1:2, and unchanged fraction of inspired oxygen (FiO2). Starting at baseline positive end-expiratory pressure (PEEP), PEEP rises by 5 cmH2O every 60 seconds to a maximum of 20 cmH2O (a smaller final increment is allowed). The same variables are recorded in the last 10 seconds of each step. After 60 seconds at PEEP 20, PEEP falls by 3 cmH2O every 60 seconds to baseline (the final decrement may vary), with measurements in each step's last 10 seconds. Original ventilator settings are restored, and measurements are repeated 60 seconds later.

  • ProcedureMethod B: Sustained Inflation Maneuver

    Before method B, the patient's original clinical ventilator settings will be maintained for at least 10 minutes to establish a stable baseline. Ventilator parameters, vital signs, end-tidal carbon dioxide (EtCO2), transcranial Doppler (TCD) parameters, and left ventricular outflow tract velocity-time integral (LVOT-VTI) will be recorded at baseline. The ventilator will then be switched to continuous positive airway pressure (CPAP) mode, applying a constant airway pressure of 25 cmH2O for 40 seconds. The same measurements will be obtained during seconds 35-40 of the maneuver. At 40 seconds, the original clinical ventilator settings will be restored immediately. The same measurements will be repeated 40 seconds after restoration as recovery measurements.

  • ProcedureMethod C: Pressure-Controlled Ventilation

    Before method C, the patient's original clinical ventilator settings will be maintained for at least 10 minutes to establish a stable baseline. Ventilator parameters, vital signs, end-tidal carbon dioxide (EtCO2), transcranial Doppler ultrasonography (TCD) parameters, and left ventricular outflow tract velocity-time integral (LVOT-VTI) will be recorded as the first set of measurements at baseline. Pressure-controlled ventilation will then be applied with positive end-expiratory pressure (PEEP) of 20 cmH2O, a set inspiratory driving pressure of no more than 15 cmH2O, a respiratory rate of 16 breaths/min, and an inspiratory-to-expiratory ratio of 1:2 for 120 seconds. The second set of the same measurements will be obtained near the end of the 120-second maneuver. The patient's original clinical ventilator settings will then be restored immediately. The third set of measurements will be obtained 60 seconds after restoration.

06

What researchers measure

Primary outcomes

  1. mean flow velocity in the middle cerebral artery

    Middle cerebral artery mean flow velocity (Vm, cm/s) will be measured using transcranial Doppler ultrasonography (TCD). In each study period, measurements will be obtained after at least 10 minutes of stable baseline ventilation. For method A, measurements will be obtained during the final 10 seconds of each 60-second PEEP step and 60 seconds after return to the original ventilation settings. For method B, measurements will be obtained at 35-40 seconds of sustained inflation and 40 seconds after return to the original settings. For method C, measurements will be obtained at baseline and 60 seconds after return to the original settings following the 120-second maneuver. No intra-maneuver TCD measurement is scheduled for method C.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

Secondary outcomes

  1. Systolic blood flow velocity (Vs) of the middle cerebral artery

    The Systolic blood flow velocity (Vs) of the middle cerebral artery will be measured by transcranial Doppler ultrasonography at the prespecified time points in each study period. The observed value and change from the period-specific baseline will be reported.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

  2. diastolic blood flow velocity (Vd) of the middle cerebral artery

    The diastolic blood flow velocity (Vd) of the middle cerebral artery will be measured by transcranial Doppler ultrasonography at the prespecified time points in each study period. The observed value and change from the period-specific baseline will be reported.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

  3. pulsatility index (PI) of the middle cerebral artery

    The pulsatility index (PI) of the middle cerebral artery will be measured by transcranial Doppler ultrasonography at the prespecified time points in each study period. The observed value and change from the period-specific baseline will be reported.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

  4. resistance index(RI) of the middle cerebral artery

    The resistance index(RI) of the middle cerebral artery will be measured by transcranial Doppler ultrasonography at the prespecified time points in each study period. The observed value and change from the period-specific baseline will be reported.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

  5. Arterial partial pressure of carbon dioxide (PaCO2)

    PaCO2 (mmHg) will be measured by arterial blood gas analysis before and after each lung recruitment maneuver. The measured values and the change from the pre-maneuver value will be reported for each study period.

    Time frame: Before and after each lung recruitment maneuver in each of up to three study periods, with at least 12 hours between periods.

  6. Arterial partial pressure of oxygen (PaO2)

    PaO2 (mmHg) will be measured by arterial blood gas analysis before and after each lung recruitment maneuver. The measured values and the change from the pre-maneuver value will be reported for each study period.

    Time frame: Before and after each lung recruitment maneuver in each of up to three study periods, with at least 12 hours between periods.

  7. Arterial blood pH

    Arterial blood pH will be measured by arterial blood gas analysis before and after each lung recruitment maneuver. The measured values and the change from the pre-maneuver value will be reported for each study period.

    Time frame: Before and after each lung recruitment maneuver in each of up to three study periods, with at least 12 hours between periods.

  8. Arterial blood lactate concentration

    Arterial blood lactate concentration (mmol/L) will be measured by arterial blood gas analysis before and after each lung recruitment maneuver. The measured values and the change from the pre-maneuver value will be reported for each study period.

    Time frame: Before and after each lung recruitment maneuver in each of up to three study periods, with at least 12 hours between periods.

  9. Left ventricular outflow tract velocity-time integral (LVOT-VTI)

    LVOT-VTI (cm) will be measured by Doppler echocardiography at the same prespecified time points as transcranial Doppler measurements in each study period. The measured value and its change from the period-specific pre-maneuver baseline will be reported. For method C, measurements are scheduled only at baseline and during recovery, not during the 120-second maneuver.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

  10. End-tidal carbon dioxide (EtCO2)

    EtCO2 (mmHg) will be monitored by capnography. A valid end-expiratory value will be recorded at the same prespecified time points as the TCD and LVOT-VTI measurements in each study period. The measured value and change from the period-specific baseline will be reported. If no valid expiratory waveform is available at a time point, the value will be recorded as missing.In the Time Frame, "return" refers to restoration of the patient's original clinical ventilator settings.

    Time frame: 3 periods (at least 12 hours apart): baseline; method A, final 10 seconds at each 60-second PEEP level and 60 seconds after return; method B, 35-40 seconds and 40 seconds after return; method C, near 120 seconds and 60 seconds after return.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol

Time frame: Beginning 6 months after publication of the main study results and available for 3 years.

Access criteria: Qualified researchers may submit a written request including research purpose, analysis plan, requested data elements, and data protection measures. Requests will be reviewed by the principal investigator and the institution.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 6, 2026
First posted
Nov 20, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Apr 1, 2028
CompletionEst.
May 1, 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951645
Lead sponsor
First People's Hospital of Chenzhou
Responsible party
Xingui Dai (Principal Investigator, First People's Hospital of Chenzhou) — Principal investigator
First posted
Nov 20, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Apr 1, 2028 (estimated)
Completion
May 1, 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Xingui Dai, PHD
Contact
20685562@qq.com
18175708210
Xingui Dai PhD, PHD
study chair · Chen Zhou NO.1 People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion